CDKN2A and neoplasm: Transgenic S100β-v-erbB mice in which a transforming allele of EGFR, v-erbB, is expressed under the control of murine S100β promotor developed low-grade oligodendroglioma, and further deleting ink4a/arf or p53 increased tumor grade and penetrance (91).